Across multiple studies (N=593), PYLARIFY (piflufolastat F 18) injection PET/CT was well-tolerated, with no individual adverse reaction occurring in more than 2% of patients1

Adverse reactions that occurred in >0.5% of men who received PYLARIFY® (n=593)*

Table showing adverse reaction rates from PYLARIFY® clinical trials. Table showing adverse reaction rates from PYLARIFY® clinical trials.

*In addition, a hypersensitivity reaction was reported in 1 patient (0.2%) with a history of allergic reactions.

Review case studies 
from PYLARIFY  
clinical studies

Learn more

Actor portrayals

CT=computed tomography; PCa=prostate cancer; PET=positron emission tomography.

INDICATION & IMPORTANT
SAFETY INFORMATION

PYLARIFY (piflufolastat F 18) Injection is a radioactive diagnostic agent indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer:

  • with suspected metastasis who are candidates for initial definitive therapy.
  • with suspected recurrence based on elevated serum prostate-specific antigen (PSA) level.

Radiation Risks

Diagnostic radiopharmaceuticals, including PYLARIFY, expose patients to radiation. Radiation exposure is associated with a dose-dependent increased risk of cancer. Ensure safe handling and preparation procedures to protect patients and health care workers from unintentional radiation exposure. Advise patients to hydrate before and after administration and to void frequently after administration.

INDICATION

PYLARIFY® (piflufolastat F 18) Injection is a radioactive diagnostic agent indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer:

  • with suspected metastasis who are candidates for initial definitive therapy.
  • with suspected recurrence based on elevated serum prostate-specific antigen (PSA) level.

References

  1. PYLARIFY® [package insert]. North Billerica, MA: Progenics Pharmaceuticals, Inc., a Lantheus company.